Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 5:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 130 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Surgical Resection of Melanoma Clear all
Completed Phase 3 Interventional Results available

Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma

NCT02388906
View directory record Official record
Conditions
Melanoma
Interventions
Ipilimumab, Nivolumab, Placebo matching Ipilimumab, Placebo matching Nivolumab
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
15 Years and older
Enrollment
906 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
35
States / cities
Little Rock, Arkansas • La Jolla, California • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2025 · Synced Oct 4, 2026, 5:49 AM EDT
Withdrawn Phase 2 Interventional

Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma

NCT03220009
View directory record Official record
Conditions
Cervical Carcinoma, Esophageal Carcinoma, Mucosal Melanoma, Mucosal Melanoma of the Head and Neck, Oral Cavity Mucosal Melanoma, Recurrent Melanoma, Stage II Vulvar Cancer AJCC v7, Stage III Vulvar Cancer AJCC v7, Stage IIIA Vulvar Cancer AJCC v7, Stage IIIB Vulvar Cancer AJCC v7, Stage IIIC Vulvar Cancer AJCC v7, Stage IV Oral Cavity Cancer AJCC v6 and v7, Stage IV Vulvar Cancer AJCC v7, Stage IVA Oral Cavity Cancer AJCC v6 and v7, Stage IVB Oral Cavity Cancer AJCC v6 and v7, Stage IVC Oral Cavity Cancer AJCC v6 and v7, Vaginal Carcinoma
Interventions
Conventional Surgery, Ipilimumab, Laboratory Biomarker Analysis, Nivolumab, Patient Observation, Radiation Therapy
Procedure · Biological · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 3, 2018 · Synced Oct 4, 2026, 5:49 AM EDT
Active, not recruiting Phase 1 Interventional

NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma

NCT04930783
View directory record Official record
Conditions
Melanoma, Metastatic Melanoma
Interventions
CDX-301, NEOVAX, Nivolumab, Pembrolizumab
Drug · Biological
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 25, 2026 · Synced Oct 4, 2026, 5:49 AM EDT
Terminated Phase 2 Interventional Results available

Treatment With Dasatinib in Patients With Acral Lentiginous, Mucosal, or Chronic Sun-damaged Melanoma

NCT01092728
View directory record Official record
Conditions
Melanoma
Interventions
Dasatinib, Surgical Resection
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 5, 2016 · Synced Oct 4, 2026, 5:49 AM EDT
Completed Phase 2 Interventional Results available

Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma

NCT00060333
View directory record Official record
Conditions
Recurrent Melanoma
Interventions
radiation therapy
Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2016
U.S. locations
39
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Joliet, Illinois + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2017 · Synced Oct 4, 2026, 5:49 AM EDT
Completed Phase 2 Interventional Results available

Phase II Trial of Neoadjuvant Temozolomide in Melanoma Patients With Palpable Stage III or IV Disease Undergoing Complete Surgical Resection

NCT00588341
View directory record Official record
Conditions
Melanoma, Skin Cancer, Cancer
Interventions
Temozolomide
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 1, 2016 · Synced Oct 4, 2026, 5:49 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Phase 1/2 Study of BA3071 in Patients With Solid Tumors

NCT05180799
View directory record Official record
Conditions
NSCLC, Melanoma
Interventions
BA3071, Nivolumab, Pembrolizumab, Pemetrexed (Alimta)
Biological · Drug
Lead sponsor
BioAtla, Inc.
Industry
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
9
States / cities
Los Angeles, California • Atlanta, Georgia • Dyer, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2025 · Synced Oct 4, 2026, 5:49 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma

NCT04099251
View directory record Official record
Conditions
Melanoma
Interventions
Nivolumab, Placebo
Biological · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
12 Years and older
Enrollment
790 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
32
States / cities
Birmingham, Alabama • Tucson, Arizona • Springdale, Arkansas + 24 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 4, 2026, 5:49 AM EDT
Completed Phase 2 Interventional Results available

Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases

NCT00587964
View directory record Official record
Conditions
Brain Metastasis, Bladder Cancer, Breast Cancer, Cervical Cancer, Colon Cancer, HEENT Cancer, Lung Cancer, Melanoma, Pancreatic Cancer, Prostate Cancer, Rectal Cancer, Sarcoma, Testicular Cancer
Interventions
Stereotactic Radiosurgery
Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 22, 2016 · Synced Oct 4, 2026, 5:49 AM EDT
Terminated Phase 2 Interventional Results available

Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement

NCT04221438
View directory record Official record
Conditions
Melanoma of Unknown Primary, Metastatic Malignant Neoplasm in Lymph Node, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Recurrent Cutaneous Melanoma
Interventions
Binimetinib, Conventional Surgery, Encorafenib, Fluorothymidine F-18
Drug · Procedure · Other
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
10
States / cities
Los Angeles, California • Ann Arbor, Michigan • City of Saint Peters, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 4, 2026, 5:49 AM EDT
Active, not recruiting Phase 3 Interventional

Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma

NCT04949113
View directory record Official record
Conditions
Malignant Melanoma Stage III
Interventions
Neoadjuvant ipilimumab + nivolumab, Adjuvant nivolumab
Drug
Lead sponsor
The Netherlands Cancer Institute
Other
Eligibility
16 Years and older
Enrollment
423 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
2
States / cities
Los Angeles, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 8, 2024 · Synced Oct 4, 2026, 5:49 AM EDT
Completed No phase listed Observational Results available

A Study to Compare Quality of Life and Compliance in Patients Receiving High-dose Interferon Versus Pegylated Interferon in Patients With Surgically Resected Melanoma

NCT01986712
View directory record Official record
Conditions
Melanoma
Interventions
Not listed
Lead sponsor
St. Luke's Hospital and Health Network, Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
4
States / cities
Tampa, Florida • Buffalo, New York • Bethlehem, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2025 · Synced Oct 4, 2026, 5:49 AM EDT
Recruiting Phase 1 Interventional

OBSERVE: A Pilot Study Of Omission Of Brain Metastasis Stereotactic Radiosurgery Following Resection With CNS-Active Systemic Therapy

NCT07655583
View directory record Official record
Conditions
Brain Metastasis, Stereotactic Radiosurgery, Resection, Systemic Therapy
Interventions
Systemic therapy
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 4, 2026, 5:49 AM EDT
Recruiting No phase listed Observational

ExoLuminate Study for Early Detection of Pancreatic Cancer

NCT05625529
View directory record Official record
Conditions
Pancreas Cancer, Exosomes, Extracellular Vesicles, Pancreatic Neoplasms
Interventions
Not listed
Lead sponsor
Biological Dynamics
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Oct 4, 2026, 5:49 AM EDT
Terminated Phase 3 Interventional Results available

Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients

NCT01546571
View directory record Official record
Conditions
Melanoma
Interventions
POL-103A, POL-103A without API
Biological
Lead sponsor
Polynoma LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
504 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
59
States / cities
Chandler, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 50 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2025 · Synced Oct 4, 2026, 5:49 AM EDT
Completed No phase listed Observational Results available

Peripheral T Cell Determinants of Response and Resistance to Pembrolizumab in Melanoma

NCT05105100
View directory record Official record
Conditions
Melanoma, Advanced Melanoma
Interventions
Biopsy, Biospecimen Collection
Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 4, 2026, 5:49 AM EDT
Completed Phase 2 Interventional Results available

Nivolumab in Treating Patients With Stage IIB-IIC Melanoma That Can Be Removed by Surgery

NCT03405155
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
Nivolumab
Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
4
States / cities
New Brunswick, New Jersey • New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 4, 2026, 5:49 AM EDT
Completed Phase 3 Interventional Results available

Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD).

NCT01682083
View directory record Official record
Conditions
Melanoma
Interventions
Dabrafenib, Trametinib, Placebos
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
870 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
20
States / cities
Birmingham, Alabama • Tucson, Arizona • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 4, 2026, 5:49 AM EDT
Not yet recruiting Early Phase 1 Interventional

PICSTAT Pilot Study for CD8 PET/CT-Guided Lifileucel Treatment in Advanced Melanoma

NCT07700121
View directory record Official record
Conditions
Unresectable or Metastatic Melanoma
Interventions
Resection of PET (high) and PET (low) Tumors, Lifileucel Manufacturing Clinical v Research, Chemotherapy Regimen, Lifileucel Infusion, IL-2, CD8 PET
Procedure · Biological · Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 4, 2026, 5:49 AM EDT
Terminated Phase 1 Interventional

Non-invasive Measurement of PD-L1 Levels With Positron Emission Tomography (PET) in Head and Neck Malignancies and Intracranial Metastases

NCT05408871
View directory record Official record
Conditions
Cancer Head Neck, Metastatic Cancer, Metastatic Lung Cancer
Interventions
adnectin 18F-BMS-986192 Head and Neck Cancer, adnectin 18F-BMS-986192 Brain Metastases
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 15, 2024 · Synced Oct 4, 2026, 5:49 AM EDT
Withdrawn No phase listed Observational

Mohs Micrographic Surgery and Reconstruction in the Optum Insurance Claims Database

NCT04117373
View directory record Official record
Conditions
Skin Cancer, Mohs Micrographic Surgery, Interpolated Flap Repair
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
1 Year to 99 Years
Timeline
2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 6, 2020 · Synced Oct 4, 2026, 5:49 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Dendritic Cell Therapy With Pembrolizumab for Metastatic or Unresectable Melanoma

NCT03325101
View directory record Official record
Conditions
Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
Interventions
Cryosurgery, Pembrolizumab, Pheresis, Therapeutic Autologous Dendritic Cells
Procedure · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced Oct 4, 2026, 5:49 AM EDT
Terminated Phase 1 Interventional

Ex Vivo-Activated Lymph Node Lymphocytes in Treating Patients With Stage IIIC-IV Melanoma

NCT02327390
View directory record Official record
Conditions
Stage IIIC Skin Melanoma, Stage IV Melanoma
Interventions
lymph node, X-ACT
Procedure · Biological
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 6, 2018 · Synced Oct 4, 2026, 5:49 AM EDT
Completed Phase 3 Interventional Results available

A Study to Compare Nivolumab Administered Subcutaneously vs Intravenous in Melanoma Participants Following Complete Resection

NCT05297565
View directory record Official record
Conditions
Melanoma
Interventions
Nivolumab/rHuPH20, Nivolumab
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Fort Wayne, Indiana • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 27, 2025 · Synced Oct 4, 2026, 5:49 AM EDT